Further head‐to‐head trials are expected to explore the optimal treatment strategy for advanced EGFR mutant NSCLC patients, including the conventional strategy that sets first‐generation EGFR‐TKIs as first‐line administration followed by second‐line osimertinib for T790 M mutation‐positive patients. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.